PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials

Kristopher J. Swiger, Seth S. Martin

Drug Safety · 2015 · 65 citations · 33 references

DOIFull text

Open access

Concepts

References

33